UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, seeks to be a major player in the Super Bowl of the pharmaceutical industry: a COVID-19 vaccine.
Oragenics came to its vaccine candidate through an acquisition. In May 2020 with the pandemic in its third month, the publicly traded company acquired Gainesville-based Noachis Terra. It paid $9.2 million in cash and $3 million in stock shares, for the company. Part of the deal — and part of the company’s appeal — included Noachis Terra’s worldwide, nonexclusive license for a COVID-19 vaccine candidate, TerraCoV2, from the National Institute of Allergy and Infectious Diseases, Oragenics CEO Alan Joslyn says.Learn more about Oragenics Chases Vaccine for Niche Markets.
Related news SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice>.